At the end of this session participants will be able to:
 Explain the mechanism of action of Biologics and sources of variability in exposure of biologics.
 Cite examples of several Biologics in hemato(oncology) where the dose can be optimized using model informed precision dosing and their specific challenges.
 Discuss which model informed precision dosing strategies can be used to personalize the dose in order to reduce financial and clinical toxicity.

Biologics are more and more used in hemato oncology. Evidence is growing that a more personalized dose individualization is beneficial for clinical outcome as well as reduction of clinical and financial toxicity. Combining therapeutic drug monitoring with PK-PD modelling has opened a new way of dose and therapy optimization called model-informed precision dosing. Model-informed precision dosing (MIPD) is an more advanced quantitative approach focusing on individualized dosage optimization, integrating complex mathematical and statistical models of drugs and disease combined with individual demographic and clinical patient characteristics. In this session challenges and opportunities of MIPD of Biologics in (hemato)oncology will be discussed. Several traditional biologics will be discussed, Alemtuzumab, Daratumab, Pembrolizumab, Nivolumab, as well as more complex biologics such as AT(L)G and Antibody drug conjugates (ADCs)